Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme (Nasdaq: HALO) reported strong Q1 2026 results and a new $1 billion share repurchase program, expecting at least $400 million of buybacks in 2026. Total revenue rose 42% year over year to $376.7 million, with royalty revenue up 43% to $240.7 million.
GAAP diluted EPS was $1.22 and non-GAAP diluted EPS $1.60. Halozyme reiterated 2026 guidance, including total revenue of $1.71-$1.81 billion, royalty revenue of $1.13-$1.17 billion, adjusted EBITDA of $1.125-$1.205 billion and non-GAAP EPS of $7.75-$8.25.
Halozyme (NASDAQ: HALO) announced a global collaboration and license agreement with GSK to apply Halozyme's ENHANZE® technology to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates (ADCs).
GSK will pay an upfront fee, may pay future milestones, and Halozyme will receive royalties on net sales. The first clinical trial is projected to start in 2026, and the deal includes an option for additional targets.
Halozyme (Nasdaq: HALO) and Oruka (Nasdaq: ORKA) entered a global exclusive collaboration and license agreement dated May 6, 2026, granting Oruka rights to Halozyme's Hypercon™ microparticle technology for ORKA-001 (psoriasis) and an option for one additional target.
Terms include an upfront payment, potential future milestone payments, and mid-single digit royalties to Halozyme on net sales of Hypercon-enabled products.
Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close. A conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET.
According to Halozyme, the call requires pre-registration and will be available via live webcast and replay in the company's Investors section at www.halozyme.com.
Halozyme (Nasdaq: HALO) appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove brings more than 30 years of financial leadership, including roles leading investor relations at Johnson & Johnson and serving as CFO for J&J's Pharmaceuticals business, a unit generating over $50 billion in annual revenue.
Halozyme (Nasdaq: HALO) announced a global exclusive collaboration and license with Vertex Pharmaceuticals on April 7, 2026 to apply Halozyme's Hypercon™ microparticle technology to up to three drug targets. Vertex will pay a $15 million upfront, potential future milestones, and royalties on net sales.
The agreement aims to reduce injection volume and enable at-home dosing for biologics through Hypercon's hyperconcentration capability.
Halozyme (NASDAQ: HALO) named David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay will oversee all financial operations while the company continues its search for a permanent CFO.
He brings more than 30 years of biotech financial leadership and previously served as Halozyme CFO from 2003–2009 and 2013–2015. Halozyme has engaged a leading executive search firm to identify a permanent CFO; Ramsay will remain until an appointment is made.
Halozyme (NASDAQ: HALO) announced that Johnson & Johnson received U.S. FDA approval (March 6, 2026) for TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy. The approval followed Phase 3 MajesTEC-3 data showing statistically significant PFS and OS benefits.
Key trial results: hazard ratio 0.17 for progression or death (95% CI 0.12–0.23; P<0.0001) and a three-year PFS rate of 83% after median three-year follow-up.
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will present and hold investor meetings at three upcoming conferences: TD Cowen on March 3, 2026, Leerink on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026.
Live audio webcasts will be available on the company investor relations website, with replays accessible for 90 days after each event.
Halozyme (NASDAQ: HALO) reported record full‑year 2025 total revenue of $1.397 billion, driven by $867.8 million in royalties (+52% YoY). The company completed acquisitions of Elektrofi (Hypercon) and Surf Bio, issued convertible notes, and reiterated 2026 guidance: $1.71–$1.81B revenue, $1.125–$1.205B adjusted EBITDA, and $7.75–$8.25 non‑GAAP EPS.
Net income was $316.9M (includes $284.9M acquired IPR&D); cash and equivalents declined to $145.4M.